Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: Effect of indole-3-carbinol

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4907-4914

  Lyn Cook, Beverly D ^a   Mohammed, Sulma I ^b   Davis, Cornelius ^a   Word, Beverly ^a   Haefele, Aaron ^a   Wang, Honggang ^a   Hammons, George ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Gemcitabine; Indole 3 carbinol; Pancreatic cancer; Sex differences

Indexed keywords

3 INDOLEMETHANOL; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEMCITABINE;

ARTICLE; CANCER CELL; CARCINOGENESIS; CYTOTOXICITY; DNA METHYLATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA MODIFICATION METHYLASES; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; INDOLES; MALE; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX FACTORS;

EID: 78751474674     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422, 2009.
2. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
3. Akada M, Crnogarac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S and Lemoine NR: Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11: 3094-3101, 2005.
4. Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL 3rd, Giguere JK and Abbruzzese JL: A phase II study of farnesyl transferase inhibitor Rl 15777 in pancreatic cancer: a Southwest Oncology Group (SW)G 9924) study. Invest New Drugs 23: 485-487, 2005.
5. Bramhall SF, Rosemurgy A, Brown PD, Bowry C and Buckels JAC: Marimastat as first line therapy for patients with unresectable pancreatic cancer: a randomized trail. J Clin Oncol 19:3447-3454, 2001.
6. Cohen SJ and Meropol NJ: Drug development in pancreatic cancer: finally, biology begets therapy. Int J Gastrointest Cancer 32; 91-106, 2002.
7. Rivera F, Lopez-Tarruella S, Vega-Villega ME and Salcedo M: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Retreatment Rev 35: 335-339, 2009.
8. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappa-B-regulated gene products. Cancer Res 67: 3853-3861, 2007.
9. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D and Ben-Yosef R: Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 25: 411-418, 2007.
10. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S and Aggarwal BB: Resveratrol, a multitarget agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 15: 257-268, 2010.
11. Rahman KM, Aranha FH, and Sarkar FH: Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 45: 101-112, 2003.
12. Frydoonfar HR, McGrath DR and Spigelman AD: Inhibition of proliferation of a colon cancer cell line by indole-3-carbinol. Colorectal Dis 4: 205-207, 2002.
13. Nachshon-Kedmi M, Yannai S, Haj A and Fares FA: Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41: 745-752, 2003.
14. Bradlow HL, Michniviez J, Telang NT and Osborne MP: Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574,1991.
15. He YH, Friesen MD, Ruch RJ and Schut HA: Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methy1-6-phenylimidazo [4,5-b]pyridine (PhIP) carcinogenesis: inhibition of PhIP-DNA adduct formation, acceleration of PhIP metabolism, and induction of cytochromome P450 in females F344 rats. Food Chem Toxicol 55: 15-23, 2000.
16. Wattenberg LW and Loub WD: Inhibition of polycyclic aromatic hydrocarbon- induced neoplasia by naturally occurring indoles. Cancer Res 38: 1 410-1413, 1978.
17. Bradfield CA and Bjeldanes LF: Effect of dietary indole-3-carbinol on intestinal and hepatic monooxygenase, glutathione 5-transferase and epoxide hydrolase activities in the rat. Food Chem Toxicol 22: 977-982, 1984.
18. Chen I, Safe S and Bjeldanes LF: Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol 51: 1069-1076, 1996. (Pubitemid 26104627)
19. Firestone GL and Bjeldanes LF: Indole-3-carbinol and 3-3′- diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter Sp 1 transcription factor interactions. J Nutr 133: 2448S-2455S, 2003.
20. Haefele A, Word B, Yongmei, X, Hammons GJ and Lyn-Cook BD: Indole-3-carbinol (I3C) modulates expression of DNA methyltransferases 1, 3a, and 3b in pancreatic cancer cells: Effects of gender and a novel (C→T) polymorphism in the promoter region of DNMT 3b. Int J Cancer Prevention 2: 245-255, 2007.
21. Girault I, Tozlu S, Lidereau R and Bieche I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9: 4415-4422, 2003.
22. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y and Hirohashi S: DNA methyltransferase expression and DNA methylation of CpG islands and pericentromeric satellite regions in human colorectal and stomach cancers. Int J Cancer 91: 205-212, 2001.
23. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA and Jones PA: The human DNA methyltransferases (DNMTs) 1, 3a, and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27: 2292-2298, 1999.
24. Wu J, Issa JP, Herman J, Bassett DE Jr, Nelkin BD and Baylin SB: Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc Natl Acad Sci U.S.A. 90: 8891-8895,1993.
25. Auerkari EI: Methylation of tumor suppressor genes p16(lNK4a), p27(Kipl), and E-cadherin in carcinogenesis. Oral Oncol 42: 5-13, 2006.
26. 1NK4a as detected in pancreatic secretions. Br J Cancer 88: 217-222, 2003.
27. Lev-Ari, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, Figer A and Arber N: Curcumin synergistically potentiates the growth inhibitory and pro- apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59 (Suppl.2): S276-S280, 2005.
28. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ: The nuclear factor-KB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999.
29. Wang Z, Zhang Y, Banerjee S, Li Y and Sarker FH: Inhibition of nuclear factor-KB activity by genistein is mediated via Notch1 signaling pathway in pancreatic cancer cells. Int J Cancer 118: 1930-1936, 2006.
30. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J and Sarkar FH: Potentiation of the effect of erlotnib by genistein in pancreatic cancer: the role of Akt and nuclear factor-KB. Cancer Res 66: 10553-10559, 2006.
31. Rogan EG: The natural chemopreventive compound indole-3-carbinol: state of the science. In vivo 20: 221-228, 2006.
32. Lian JP, Word B, Taylor S, Hammons GJ and Lyn-Cook BD: Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res 23: 3-7, 2004.
33. Jeon KI, Rih JK, Kim HJ, Lee YJ, Cho CH, Goldberg ID, Rosen EM and Bae I: Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 544: 246-251, 2003.
34. Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF and Firestone GL: Indole-3-carbinol and tamoxifen cooperates to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59: 1244-1251, 1999.
35. INK4A participates in a Gl arrest checkpoint in response to DNA damage. Mol Cell Biology 18: 378-387, 1998.
36. CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biology 16: 859-867, 1996.
37. Peng D-F, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S and Hirohashi S: DNA methylation of multiple tumor-related genes in association with the overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27: 1160-1168, 2006.
38. Mini E, Nobilli S, Caciagli B, Landini I and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5): v7-12, 2006.
39. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D and Iacobuzio-Donahue CA: Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12: 2492-2497, 2006
40. Antonsson BE, Avramis VI, Nyce J and Holcenberg JS: Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/) and CCRF/CEM/ddCK-1. Cancer Res 47: 3672-3678, 1987.
41. Chabner BA, Johns DG, Coleman CN, Drake JC and Evans WH: Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 53: 287-290, 1974.
42. Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, van den Ijssel P, Ylstra B and Peters GJ: Microarray analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleic Acids 25: 1001-1007, 2006.